DATALYTYX LIMITED

1. Financial Health Score: A-

Datalytyx Limited receives an excellent financial health score of A-. The business demonstrates robust vitality, characterised by rapidly growing equity, a dramatic improvement in cash reserves, and strong profitability. The only slight concern preventing a perfect score is the presence of a large, unspecified block of short-term "other creditors," which requires monitoring to ensure it does not represent toxic debt. Overall, the company is in peak physical condition.

2. Key Vital Signs

• Cash Pulse (Liquidity): £2,469,378 (up from £475,261 in 2019). The company's cash flow—the lifeblood of any business—has surged by over 400%. This indicates a remarkably healthy circulation of capital, ensuring the business can comfortably meet its operational needs and weather short-term shocks.
• Muscle Mass (Retained Earnings): £1,704,208 (up from £413,728 in 2019). The company has built significant muscle over the year, retaining £1.29 million of profits. This demonstrates that the business is not just generating revenue, but effectively converting it into sustainable strength.
• Bone Density (Net Assets): £3,424,208 (up from £2,333,728 in 2019). The overall structural foundation of the company is highly robust. Net assets have grown by nearly 47% year-on-year, indicating a solid and resilient frame.
• Immune System (Current Ratio): 1.3x (Current Assets of £4.36M / Current Liabilities of £3.34M). The company has a healthy buffer to fight off short-term obligations. However, a closer look reveals that £2.53M of the current liabilities are "other creditors," which warrants a deeper diagnostic to ensure these obligations are manageable.

3. Diagnosis

Overall Condition: Excellent, with a minor anomaly to monitor.

Datalytyx Limited presents the financial picture of a highly vigorous, rapidly maturing IT consultancy. Between 2015 and 2018, the business operated with very thin cash reserves (often under £250k), relying on operational revenue to keep the lights on—a stressful state akin to running a marathon on an empty stomach.

In the financial year ending June 2020, the patient underwent a remarkable transformation. The dramatic increase in cash and retained earnings suggests the company has successfully scaled its operations, likely secured major contracts, or optimised its billing cycles. The investment of £1.32M in group undertakings also shows a healthy expansion of its corporate footprint.

However, like a routine blood test revealing a slightly elevated marker, the £2.53M in "other creditors" due within one year is a symptom that requires attention. In a healthy, cash-rich company, this often represents deferred income (cash received for services not yet delivered) or intercompany loans from group entities, rather than stressful debt. Given the company's cash position and the group investments, this is likely benign, but it should be verified.

4. Recommendations

• Diagnostic Follow-up on "Other Creditors": Conduct an internal review of the £2.53M in other creditors. Confirm whether this represents deferred income, intercompany loans, or accrued expenses. Understanding this liability will ensure the company's working capital is not suddenly eroded by an unexpected payment.
• Cash Fitness Regimen: With over £2.4M sitting in the bank, the company is holding more cash than ever before. While this provides excellent security, consider whether a portion of this capital could be invested into higher-yield instruments or further R&D (as seen with the £560k added to intangible assets this year) to accelerate long-term growth.
• Monitor Share-based Payment Vitality: The company has granted significant share options (over 11 million shares) under EMI and unapproved schemes. While excellent for staff retention, ensure that the potential future dilution is modelled and managed proactively so that the equity health of the PSCs (Persons with Significant Control) remains balanced.